Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Lung Institute
AddedFeb 15, 2024
UpdatedJun 18, 2026
Lung Institute

Lung Institute

Dallas-based Lung Institute: Pioneers in regenerative medicine, offering innovative, minimally invasive stem cell therapies for debilitating lung disorders.

HQ
Tampa, FL, US
Founded
2013
Overview
Compare
Fundraising
Employees
Website

Founded in Dallas, the Lung Institute is a pioneering healthcare organization focused on regenerative medicine. Their core mission is to offer innovative, minimally invasive stem cell therapies to treat debilitating lung disorders such as chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, emphysema, and interstitial lung disease. The Lung Institute aims to improve patients' quality of life by providing more effective treatment options for these severe pulmonary conditions.

The Lung Institute has garnered global recognition through the expertise of its physicians and their dedicated practices. Notable achievements include advancements in stem cell therapy techniques that have significantly impacted patient outcomes. The organization has also attracted attention from leading investors in the healthcare sector, further solidifying its reputation as a leader in regenerative medicine. Through its innovative treatments, the Lung Institute has made a substantial impact on the lives of those suffering from chronic lung diseases.

Lung Institute - Similar Companies

Pulmatrix logo

Pulmatrix

pulmatrix.com

RhinoCyte logo

RhinoCyte

rhinocyte.com

AlphaStem logo

AlphaStem

alpha-stim.com

Pulmonx logo

Pulmonx

pulmonx.com

Lung Biotechnology logo

Lung Biotechnology

unither.com

Celltex Therapeutics logo

Celltex Therapeutics

celltexbank.com

PulmonIx logo

PulmonIx

pulmonix.com

U.S. Stem Cell logo

U.S. Stem Cell

us-stemcell.com

Regen BioPharma logo

Regen BioPharma

Personalized Stem Cells logo

Personalized Stem Cells

Nimbus Health logo

Nimbus Health

nimbushealth.com

LaCell logo

LaCell

Alveolus Bio logo

Alveolus Bio

alveolusbio.com

Pulmokine logo

Pulmokine

pulmokine.net

Hepatx logo

Hepatx

hepatx.com

Lung Institute - Quick Facts

Who are Lung Institute's competitors?

Companies similar to Lung Institute include Pulmatrix, RhinoCyte, AlphaStem and Pulmonx.

When was Lung Institute founded?

Lung Institute was founded in 2013.

Where is Lung Institute's headquarters located?

Lung Institute's headquarters is located in Tampa, FL, US.

When was Lung Institute's last funding round?

Lung Institute's most recent funding round was for $232k (USD) in March 2015.

How much has Lung Institute raised to-date?

As of Mar 31, 2015, Lung Institute has raised a total of $232k (USD).

How many employees does Lung Institute have?

Lung Institute has 11 employees as of Feb 4, 2024.

Lung Institute - Classification

Ownership
  • Private
Technology
  • Biotech
  • HealthTech
Geographic Exposure
  • United States
Revenue
  • Recurring
Main Product
  • Stem Cell Therapy
Tags
  • Clinic
  • Healthcare
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
ISIC
  • 8620Medical and dental practice activities
Show 7 more industry codes
NAICS
  • 621000Ambulatory Health Care Services
  • 621100Offices of Physicians
  • 621110Offices of Physicians
  • 621111Offices of Physicians (except Mental Health Specialists)
  • 623000Nursing and Residential Care Facilities
SIC
  • 8010Offices And Clinics Of Doctors Of Medicine
  • 8011Offices And Clinics Of Doctors Of Medicine